Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.55 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.52 |
| ▸ | GRM5 | P41594 | 8/20 | 0.52 |
| ▸ | WNT3A | P56704 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | CDK7 | P50613 | 1/20 | 0.46 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.46 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14790770 | 0.90 | NAMPT (0.56) | NAMPTPDK4GRM1GRM5WNT3A | |
| SCHEMBL14990423 | 0.88 | NAMPT (0.57) | NAMPTPDK4GRM1GRM5WNT3A | |
| SCHEMBL17876418 | 0.86 | NAMPT (0.57) | NAMPTPDK4GRM1GRM5WNT3A | |
| SCHEMBL14710349 | 0.86 | NAMPT (0.53) | NAMPTPDK4GRM1GRM5WNT3A | |
| SCHEMBL22325023 | 0.85 | NAMPT (0.56) | NAMPTPDK4GRM1GRM5WNT3A | |
| SCHEMBL19989639 | 0.85 | NAMPT (0.67) | NAMPTPDK4GRM1GRM5HTR6 | |
| SCHEMBL2239831 | 0.84 | NAMPT (0.66) | NAMPTPDK4GRM1GRM5HTR6 | |
| SCHEMBL8912847 | 0.84 | NAMPT (0.63) | NAMPTPDK4GRM1GRM5HTR6 | |
| SCHEMBL22340252 | 0.84 | NAMPT (0.55) | NAMPTPDK4GRM1GRM5WNT3A | |
| SCHEMBL31198982 | 0.84 | NAMPT (0.58) | NAMPTPDK4GRM1GRM5HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110177055-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-07-21 | — | — | US | disclosed |
| US-20110177055-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-07-21 | — | — | US | disclosed |
| US-7939547-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-10 | — | — | US | disclosed |
| US-7939547-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-10 | — | — | US | disclosed |
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | PRSS1, PRSS8, PRSS2 | NAMPT 730/4885PDK4 3853/4885GRM1 3917/4885 |
| US-20110177055-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS1, PRSS8, PRSS2 | NAMPT 739/4885PDK4 3868/4885GRM1 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.